NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Suda Pharmaceuticals Ltd (F: E4N)

 
E4N Technical Analysis
5
As on 27th Dec 2021 E4N STOCK Price closed @ 0.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.02 & Strong Sell for SHORT-TERM with Stoploss of 0.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

E4NSTOCK Price

Open 0.01 Change Price %
High 0.01 1 Day -0.01 -50.00
Low 0.01 1 Week -0.01 -50.00
Close 0.01 1 Month -0.01 -50.00
Volume N/A 1 Year -0.01 -50.00
52 Week High 0.05 | 52 Week Low 0.01
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
HGF2 7.40 1380.00%
 
F Germany Top Losers Stocks
CMID 0.00 -100.00%
CMID 0.00 -100.00%
CMID 0.00 -100.00%
3MW 0.00 -100.00%
3MW 0.00 -100.00%
BRTN 0.00 -100.00%
BRTN 0.00 -100.00%
2TU 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
 
 
E4N
Daily Charts
E4N
Intraday Charts
Whats New @
Bazaartrend
E4N
Free Analysis
 
E4N Important Levels Intraday
RESISTANCE0.01
RESISTANCE0.01
RESISTANCE0.01
RESISTANCE0.01
RESISTANCE0.01
RESISTANCE0.01
RESISTANCE0.01
RESISTANCE0.01
 
E4N Forecast November 2024
4th UP Forecast0.05
3rd UP Forecast0.04
2nd UP Forecast0.03
1st UP Forecast0.02
1st DOWN Forecast-0
2nd DOWN Forecast-0.01
3rd DOWN Forecast-0.02
4th DOWN Forecast-0.03
 
E4N Weekly Forecast
4th UP Forecast0.01
3rd UP Forecast0.01
2nd UP Forecast0.01
1st UP Forecast0.01
1st DOWN Forecast0.01
2nd DOWN Forecast0.01
3rd DOWN Forecast0.01
4th DOWN Forecast0.01
 
E4N Forecast2024
4th UP Forecast0.09
3rd UP Forecast0.06
2nd UP Forecast0.05
1st UP Forecast0.03
1st DOWN Forecast-0.01
2nd DOWN Forecast-0.03
3rd DOWN Forecast-0.04
4th DOWN Forecast-0.07
 
 
E4N Other Details
Segment EQ
Market Capital 14167692.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
E4N Address
E4N
 
E4N Latest News
 
Your Comments and Response on Suda Pharmaceuticals Ltd
 
E4N Business Profile
Suda Pharmaceuticals Ltd, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. The company's product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; Sumatriptan, an oral spray formulation for the treatment of migraine headache; and Anagrelide to treat cancer. It has a license and supply agreement with Cann Pharmaceutical Australia Limited to develop an oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug-resistant epilepsy, melanoma and Sanofi; and collaborative research agreement with Imperial College London. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia. Address: 55 Howe Street, Osborne Park, WA, Australia, 6017
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service